Bulletin: Coca-Cola Amatil Ratings Unchanged After 2007 Results Meet Expectations Feb 08

  • ID: 2042802
  • February 2008
  • Standard & Poors
1 of 3

MELBOURNE (Standard & Poor's) Feb. 13, 2008--Standard & Poor's Ratings Services said today that its 'A-/Stable/A-2' corporate credit ratings and outlook on Coca-Cola Amatil Ltd. (CCA) are unaffected after CCA's financial results for the year ended Dec. 31, 2007 were within our expectations. EBIT from continuing operations (which exclude CCA's recently sold South Korean operations) rose by 15.3% to A$648.4 million in 2007, underpinned by a strong performance from the company's Australian and New Zealand beverage businesses, an improved result from the Indonesian operations, and an increasing contribution from the growing alcohol beverages business. Improved pricing and product mix, together with a number of successful new product launches, helped offset higher commodity input costs. The sale of CCA's South Korean...

Companies mentioned in this report are: Coca-Cola Amatil Ltd.
Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Coca-Cola Amatil Ltd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.